Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults. The pathophysiology of AD is complex and involves skin barrier and immune dysfunction. 
| INTRODUC TI ON
Atopic dermatitis (AD) is an inflammatory skin disease that affects between 15% and 30% of children and 2% and 10% of adults worldwide. [1] [2] [3] Although multiple therapeutic options are available for the management of AD, [4] [5] [6] [7] until crisaborole was approved in the United
States in December 2016, no topical medications with novel mechanisms of action had been approved for approximately 15 years. [8] Use of topical corticosteroids (TCSs), the mainstay of AD therapy, decreases acute and chronic signs of AD and pruritus and is effective in treating active inflammatory disease. [4, 6, 7, 9, 10] However, use of TCSs is associated with adverse events (AEs) such as telangiectasia, striae, rosacea and acne, whereas prolonged application of moderate to potent TCSs is associated with skin atrophy. [11, 12] Some TCSs, like mometasone furoate, have been reported to have lower atrophogenic potential. [13] Topical calcineurin inhibitors (TCIs) became an alternate treatment option when tacrolimus and pimecrolimus were first approved for use in AD. [11] Although TCIs have demonstrated effectiveness in treating AD, they can induce local skin burning and stinging. [11, 14] Prescribing information for TCIs include a boxed warning in the United States for a theoretical risk of malignancy, although after years of use, no evidence that topical application can cause malignancy has emerged. [11, [14] [15] [16] Proactive use of TCIs after AD is controlled can result in longlasting flare-free periods and decrease the need for TCSs, leading to improvement in skin lesions and quality of life. [17] Proactive use of the medium-potency TCS fluticasone propionate (acute phase: twice daily; maintenance phase: 4 weeks of once-daily dosing 4 d/wk, followed by 16 weeks of once-daily dosing 2 d/wk) did not result in skin atrophy, which might otherwise occur as a result of improper reactive use, suggesting that maintenance use for prevention of flares could mitigate some of the limitations of these agents. [17, 18] Other treatment methods include phototherapy, commonly with narrow-band ultraviolet B (UVB) light, which is used primarily as add-on therapy to TCSs. Systemic treatments include immune suppressants such as cyclosporine, azathioprine, methotrexate and mycophenolate mofetil, which are sometimes used in severe or refractory AD. [5] [6] [7] 19, 20] Recently, the anti-interleukin 4 receptor (IL-4Rα) monoclonal antibody dupilumab was approved in the United
States and Europe for use in adults with moderate to severe AD. [21, 22] Combinations of topical and systemic treatments may also be useful in treating moderate to severe AD, for example, topical therapies combined with cyclosporine have been shown to reduce duration and dose of cyclosporine while achieving positive clinical results and prolonged disease remission. [23] Phosphodiesterase 4 (PDE4) inhibition may be an alternative for long-term treatment of AD. [24] The enzyme PDE4 is found in a variety of immune cells and breaks down cyclic adenosine monophosphate (cAMP). [25, 26] Increases in cAMP levels as a result of PDE4 inhibition in cellular studies of atopic leucocytes have been associated with the suppression of proinflammatory molecules such as IL-4 and prostaglandin E 2 , suggesting that inhibition of PDE4 may decrease the inflammatory processes associated with AD. [24, 27, 28] 
| PATHOPHYS IOLOGY OF AD
Atopic dermatitis is characterized by skin inflammation, acute and chronic eczematous lesions and intense pruritus. [29] [30] [31] Major advances in the past 10 years have shown that skin barrier dysfunction and immune activation participate in the complex pathophysiology of AD. [32] [33] [34] [35] AD is believed to result primarily from overexpression of the T helper (Th) 2 cytokine axis; however, Th22, Th17 and Th1 cytokine pathways may also play a role ( Figure 1 ). [33, 35] This overexpression leads to an accumulation of dendritic cells, particularly inflammatory dendritic epidermal cells (IDECs) in skin lesions. [36] [37] [38] [39] Increased Th17 activation has also been observed in Asian patients, [40] and reduced counter-regulation by Th1 T cells has been observed in children. [41] Increased levels of Th2 cytokines such as IL-4, IL-5, IL-13, IL-25, IL-31 and IL-33 and chemokines CCL17, CCL18, CCL22 and   CCL26 , as well as Th22 responses (via IL-22 and S100A proteins), have been observed in AD lesions. [31, 33, [42] [43] [44] Some Th2 and Th22 cytokines have been shown to decrease expression of terminal differentiation genes (ie, filaggrin), which contributes to skin barrier defects. [33, [44] [45] [46] Increased IL-31 is associated with itch and elongation and branching of IL-31 receptor A-positive sensory nerve fibres, and administration of the anti-IL-31 receptor A monoclonal antibody nemolizumab to patients with AD resulted in significant reduction in the severity of pruritus compared with placebo. [33, 47, 48] Conversely, IL-22 mediates epidermal hyperplasia. [33, 49] The Th2 cytokines IL-4 and IL-13 are thought to have a pathogenic role in AD. [33] Single-nucleotide polymorphisms have been observed in the genes for IL-4 and IL-13 and their receptors in patients with AD. [33, [50] [51] [52] [53] IL-4 and IL-13 have been linked to inhibition of production of antimicrobial peptides and have been observed to override other skin immune defense mechanisms in patients with AD. [33, 54, 55] This is of special importance because of the susceptibility of AD patients to eczema herpeticum. [56] Skin barrier dysfunction and decreased expression of antibacterial peptides can lead to subsequent infection and allergen sensitivity in AD. [33] IL-4 and IL-13 are targeted by dupilumab, which can reverse clinical and molecular tissue characteristics of AD. [57] [58] [59] Upregulation of Th17 and Th1 cytokines and chemokines is also detected in AD lesions. Components of the Th17 pathway such as IL-17, IL-17A, CXCL1, elafin (PI3) and CCL20 are upregulated in acute and chronic AD. [31, 33] They also contribute to skin barrier dysfunction by downregulating filaggrin or by upregulating inflammatory molecules such as S100A proteins. [33, 49, 60] In chronic AD, Th2
and Th22 remain upregulated with the addition of activated Th1 response, which includes interferon gamma (IFNγ) and CXCL9, and CXCL10. [31, 33] In addition to changes in immune cells, AD is associated with skin barrier dysfunction characterized by increased stratum corneum pH, increased transepidermal water loss and decreased stratum corneum hydration. [61] Epidermal abnormalities include defects in terminal differentiation of keratinocytes, as well as epidermal hyperplasia and induction of S100As. [33, 62, 63] In addition to dysfunction in the synthesis of ceramides, reduced skin hydration in AD has also been associated with decreased sebum production suggesting that this contributes to skin barrier dysfunction. [61] The skin microbiome can also play a role in the pathophysiology of AD. Human skin is regularly colonized by microbes such as Staphylococcus spp. and Corynebacterium, and Propionibacterium (now known as Cutibacterium) genera. [64] Dominant presence of Staphylococcus epidermidis in healthy skin inhibits growth of Staphylococcus aureus which is found in ~90% of patients with AD and, of which, 50% are toxin producing. [65] Secretion of metabolites from skin microbes can result in crosstalk with the patient's immune system and regulate immune responses. [65] S aureus, in particular, has been associated with the production of extracellular vesicles that induce increased production of proinflammatory mediators in the skin resulting in AD-like inflammation. [66] Dysbiosis of skin microflora has been associated with AD pathogenesis. For example, increased colonization of S aureus has been characteristic in lesional skin and is associated with disease flares. [64] However, the complex role the microbiome in the skin is still being elucidated.
| ROLE OF PDE4 IN AD
Cyclic adenosine monophosphate has been shown to play a role in the regulation of inflammatory and immune responses, and increased levels of cAMP have been associated with effects such as suppression of T cells and monocytes. [67] PDEs are enzymes that break down cAMP or cyclic guanosine monophosphate (cGMP), and they demonstrate activity in all cells in the body. [68] [69] [70] However, certain isoenzymes are expressed only in select tissue. For example, PDE3 is preferentially expressed in the heart, lungs, liver, platelets, adipose tissue and inflammatory cells, whereas PDE7 is preferentially expressed in the heart, skeletal muscle, kidney, brain, pancreas and T lymphocytes. [69] The role of PDE4 in a broad group of immune-related diseases has been reviewed previously. [71] There are 20 variants among the PDE4 gene families of PDE4A, PDE4B, PDE4C and PDE4D. [72] With regard to AD, PDE4 is found in immune and inflammatory cells such as basophils, mast cells, eosinophils, B and T lymphocytes, monocytes, macrophages, neutrophils and endothelial cells. [73] [74] [75] Increased cAMP-PDE activity has been reported in freshly isolated mononuclear lymphocyte (MNL) preparations from patients with AD and in three patients with documented AD whose disease had been in remission for 2-20 years, despite lack of visual evidence of cutaneous inflammation. [76] Using immunohistochemistry staining, PDE4 isoforms PDE4A, PDE4B, PDE4C and PDE4D have also been observed to be increased in dermal fibroblasts of skin samples of patients with AD relative to dermal fibroblasts from healthy skin;
however, the clinical significance of each isoform is not fully understood in AD. [77] Adenylate cyclase, which catalyses adenosine triphosphate to cAMP, was found to be upregulated in MNLs in AD, thus increasing cAMP generation, which in turn is believed to drive increased PDE activity in an effort to establish a homeostatic steady state in unstimulated cells. [78] When these leucocytes are then stimulated, a further increase in cAMP production would normally dampen the cell response, however, due to the already increased levels of PDE, adequate cAMP levels cannot be maintained. [78] In addition, increased PDE activity in atopic monocytes was associated with increased prostaglandin E 2 production, resulting in increased IL-6 and increased IL-10, with both contributing to Th1/Th2 imbalance. [28] While IL-10 is typically considered a global suppressor cytokine of immune responses, increased IL-10 in AD monocytes is attributed to decreased IFNγ production by Th1 cells, shifting the balance of the Th1/Th2 ratio towards Th2 response. [28] Experiments in atopic MNL cultures showed that PDE4 inhibitors significantly reduced levels of prostaglandin E 2 , IL-10 and IL-4, as measured by immunoassay. [24] However, in some cases, PDE4 inhibitors have been observed to increase proinflammatory molecules such as IL-8 in human umbilical vein endothelial cells and in mouse lung neutrophils. [79] Based on this potential to reverse broad imbalances in immune responses in AD without the use of corticosteroids, inhibition of PDE4 was considered a desirable target to pursue in further studies (Figure 1 ).
Although the effects of PDE4 in AD are still being studied, selective PDE4 inhibition has provided additional insight regarding affected cytokines and immune markers. PDE4 inhibitors have been shown to be associated with reductions in various cytokines similarly to TCIs and TCS (Table 1) . [ [80] In a pharmacodynamics study of oral apremilast in patients with psoriatic arthritis, the biomarkers IL-8, TNFα and IL-6 were reduced at 24 weeks of treatment, and IL-17, IL-23 and IL-6 were reduced at 40 weeks. [83] Similarly, in psoriasis patients treated with oral apremilast, clinical efficacy (improvement in Psoriasis Area and Severity Index) was linked to reduction of IL-17F, IL-17A and IL-22
cytokines at week 16 of treatment. [84] To date, there is a lack of published research examining the effect of PDE4 inhibition on microbiome dysbiosis associated with AD.
| PDEINHIB ITOR S CURRENTLY AVAIL AB LE AND IN DE VELOPMENT FOR AD

| Crisaborole
Crisaborole is a nonsteroidal boron-based molecule ( Figure 2 ) that selectively inhibits PDE4. The boron moiety in the crisaborole molecule is important for its inhibitory activity, serving as a phosphate isostere in the PDE4 active site. In fact, replacement of the boron moiety with carbon (bound to either oxygen or hydroxyl group) results in loss of effective enzymatic inhibition and subsequent reduction in cytokine concentrations in peripheral blood mononuclear cells (PBMCs). [26, 91] In addition, the incorporation of boron into crisaborole's structure allows for a low molecular weight (251 Daltons) and thus easier penetration into the skin. [26] In available maximal-use and long-term studies with crisaborole, AEs were primarily mild to moderate application site reactions. [92, 93] When tested across the spectrum of PDE isoforms PDE1 through PDE11, crisaborole exhibited greater affinity for PDE4 isoforms than for other PDE families (particularly in members of isoforms PDE4A, PDE4B and PDE4D), although it did show some inhibitory activity against PDE1A, PDE3A and PDE7A. [82] Its use resulted in reduced concentration of cytokines such as TNFα, IFNγ, IL-2 and, to a lesser extent, IL-5 and IL-10 in cell studies of PBMCs stimulated by lipopolysaccharide or phytohemagglutinin. [81, 82] Crisaborole ointment, 2%, is currently the only PDE4 inhibitor approved for treatment of mild to moderate AD. [94, 95] Approval was based on the results of two identically designed multicenter, randomized (2:1), double-blind, phase 3 clinical studies that included 1522 patients (ClinicalTrials.gov identifier, AD-301: NCT02118766; AD-302: NCT02118792). [8] In both studies, patients aged ≥2 years with mild to moderate AD (according to Hanifin and Rajka criteria [96] ) and ≥5% treatable body surface area (BSA) involvement were randomly 29.7%, P < 0.001) and more patients experiencing reduction in the severity of signs and symptoms of AD and early and sustained relief from pruritus. [8] Treatment with crisaborole was well tolerated over the 4-week treatment period. Most treatment-emergent AEs were mild or moderate, and the most common treatment-related AE was application site pain (crisaborole: 4.4% and vehicle: 1.2%). [8] Because AD often necessitates prolonged treatment, longer term safety of crisaborole was explored in an open-label extension study of patients (N = 517) who completed these two phase 3 studies, revealing a similar safety profile after being treated for an additional 48-week period, with no serious treatment-related AEs. [93] Clinical testing of crisaborole in patients aged ≥2 years under maximal-use conditions demonstrated a mean maximum plasma concentration (C max ) of 127 ng/mL after 8 days of treatment. [92] Topical application minimizes the risk of systemic pharmacologic effects associated with oral PDE4 inhibition.
The current prescribing information for crisaborole ointment does not include a boxed warning and there are no restrictions on duration of use, though adverse effects such as application site pain may be a concern for patients.
| Other topical PDE4 inhibitors
Other topical PDE4 inhibitors that have been or that are currently in development for treatment of AD include E6005/RVT-501, LEO 29102, OPA-15406/MM36 and DRM02. [97] Unlike crisaborole, none of these investigational drugs contains boron; however, like crisaborole, they generally fall under the 500-Dalton rule in terms of molecular weight, allowing for skin penetration (Figure 2 ). [98] In addition, although promising results have been published for some of these agents, [99] [100] [101] [102] none has been evaluated in phase 3 studies.
E6005/RVT-501 is a topical PDE4 inhibitor that has been evaluated in several phase 1/2 studies. Results have been promising in children and adults in Japan. [100] [101] [102] For example, at 0.03% and 0.2% strengths, a significant reduction in Scoring of Atopic Dermatitis (SCORAD) index [103] score was observed in adults aged 20-60 years. [100] In children aged 2-15 years with mild to moderate clinical symptoms, the 0.2% strength demonstrated numerically greater reduction in severity per the Eczema Area and Severity Index (EASI) than did vehicle (−45.94% vs −32.26%), though it did not reach statistical significance. [101] In addition, pharmacokinetic studies have shown systemic absorption to be minimal. [104] An additional phase 2 study was recently conducted to evaluate 0.2% and 0.5% strengths in patients with AD in the United States and Canada (ClinicalTrials.
gov identifier, NCT02950922), with results expected in 2018. E6005 was more selective for PDE4 when tested against PDE isoforms PDE1 through PDE5, and it has shown modest activity in reducing IFNγ, TNFα, IL-2, IL-4 and IL-12 in PBMCs. [105] OPA-15406/MM36 was evaluated in a recent randomized, double-blind, vehicle-controlled phase 2 study in patients aged 10-70 years with mild to moderate AD. [99] OPA-15406, 1%, had a significantly higher rate of treatment success than did vehicle at 4 weeks (20.9% vs 2.7%; P = 0.0165), where success was defined as a score of 0 (clear) or 1 (almost clear), with at least a two-grade reduction from the baseline score of 2 (mild) or 3 (moderate) on the ISGA. [99] A maximal-use phase 2 study in paediatric patients (aged 2 to <18 years) with AD (ClinicalTrials.gov identifier, NCT02945657) was completed in June 2017, but results are not yet published.
OPA-15406 has exhibited highly selective inhibitory activity against PDE4 subtypes, particularly subtype B; however, the evidence has not been published. [99] LEO 29102 is another selective topical PDE4 inhibitor. [106] A dose-escalation study showed that systemic exposure was minimal, with a C max of 5.07 ng/mL at 53% BSA exposure. [106] Although a phase 2 dose-ranging study that compared several different dose strengths of LEO 29102 with pimecrolimus cream in adult patients with AD (aged 18-65 years) has been completed (ClinicalTrials.gov identifier, NCT01037881), results have not been published, and current development status is unknown. [107] LEO 29102 has been shown to selectively inhibit isoform PDE4D and exhibit some inhibitory activity towards TNFα [106] ; however, data on activity towards other PDE isoforms and other immune cytokines are unpublished.
DRM02 was evaluated in a double-blind, vehicle-controlled, phase 2 proof-of-concept study in adult patients (aged 18-70 years) with stable AD (ClinicalTrials.gov identifier, NCT01993420). The study was completed in 2014; however, results were not published. [108] Development of DRM02 was discontinued by late 2015. [109] Data on PDE isoform and cytokine inhibitory activity are unpublished.
| Oral apremilast
Apremilast is an oral PDE4 inhibitor approved for use in adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. [110] When tested for inhibitory activity against PDE isoforms PDE1 through PDE11, apremilast had activity against PDE4 isoforms of all sub-families and it did not significantly inhibit any other PDE enzymes. [111] In PBMCs, apremilast inhibited production of TNFα, IFNγ, IL-2, IL-5, IL-10, IL-13, IL-17 and granulocytemacrophage colony-stimulating factor (GM-CSF). [111] An open-label investigator-initiated study was conducted to evaluate apremilast 30 mg doses) at 3 months. [80] However, a high incidence of nausea was reported as an AE, with an incidence of 33% in the 20 mg cohort and 90% in the 30 mg cohort. [80] This study also conducted ontologic analyses of peripheral blood samples showing significant differential expression of the cAMP response element binding pathway (P < 0.001), bcl-2 antagonist of cell death phosphorylation pathway (P < 0.05), chemokine-mediated signalling (P < 0.0001), IL-12 signalling (P < 0.05), cytoskeleton remodelling (P < 0.05), and regulation of immune complex clearing by monocytes and macrophages (P < 0.0001) compared with baseline in the 20 mg cohort. [80] In the 30 mg cohort, there was significant differential expression of CCR3 signalling in eosinophils (P = 0.05). [80] A phase 2 study consisting of 185 patients was conducted to evaluate apremilast 30 mg twice daily and 40 mg twice daily against placebo in patients with moderate to severe AD (ClinicalTrials.gov identifier, NCT02087943). [112] Patients who received apremilast 40 mg twice daily had significantly greater percentage change reduction in EASI score at week 12 (primary endpoint) than those who received placebo; however, this was not observed with the 30 mg twice-daily dose. Neither treatment group was significantly better than the placebo group on all secondary endpoints. Diarrhoea and nausea were more common in the 30 and 40 mg arms (diarrhoea: 17% and 24%; nausea: 16% and 11%, respectively) than in the placebo arm (diarrhoea: 2%; nausea: 2%) over 12 weeks. [112] These gastrointestinal AEs are not typically seen in studies of topical formulations of PDE4 inhibitors, which may be because of the limited systemic exposure. Cellulitis was reported in the 40 mg arm, with an incidence of 5% over 12 weeks of treatment.
| CON CLUS I ON S/INTERPRE TATI ON
Atopic dermatitis is a complex disease caused by skin barrier dysfunction and immune dysregulation that involves many inflammatory cytokines. The limited topical treatments for patients with AD have led to development of novel nonsteroidal targeted therapies.
PDE4 plays a role in the regulation of the inflammatory cascade associated with AD inflammation, making it a desirable target of drug therapy. PDE4 inhibitors have a unique mechanism that differs from the mechanisms of TCSs and TCIs, and they affect a broad range of cytokines involved in AD. One topical PDE4 inhibitor, crisaborole, has been approved in the United States for the treatment of AD, while several other agents are currently in clinical development. The mechanism of action of crisaborole will be further characterized in a study that is underway to evaluate the efficacy and changes in key skin biomarkers in patients with mild to moderate AD (ClinicalTrials.
gov identifier, NCT03233529). Overall, evidence suggests that targeting of PDE4 may be a safe and effective approach to the management of AD. A recent review provides practical recommendations to help clinicians incorporate crisaborole into the treatment armamentarium for AD. [113] ACK N OWLED G EM ENTS 
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